These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36505840)

  • 21. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
    Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
    Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
    Aagaard L; Hansen EH
    Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.
    Wang Y; Shen S; Hu P; Geng D; Zheng R; Li X
    Cancer Med; 2022 Dec; 11(23):4491-4500. PubMed ID: 35616090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
    Wang L; Wang W
    Oncol Rep; 2021 Jan; 45(1):13-28. PubMed ID: 33200229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.
    Leone R; Conforti A; Venegoni M; Motola D; Moretti U; Meneghelli I; Cocci A; Sangiorgi Cellini G; Scotto S; Montanaro N; Velo G
    Drug Saf; 2005; 28(6):547-56. PubMed ID: 15924506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
    Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
    Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating ALK-positive non-small cell lung cancer.
    Ziogas DC; Tsiara A; Tsironis G; Lykka M; Liontos M; Bamias A; Dimopoulos MA
    Ann Transl Med; 2018 Apr; 6(8):141. PubMed ID: 29862230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
    Dubrall D; Leitzen S; Toni I; Stingl J; Schulz M; Schmid M; Neubert A; Sachs B
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):56. PubMed ID: 34620231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-related deaths: an analysis of the Italian spontaneous reporting database.
    Leone R; Sottosanti L; Luisa Iorio M; Santuccio C; Conforti A; Sabatini V; Moretti U; Venegoni M
    Drug Saf; 2008; 31(8):703-13. PubMed ID: 18636789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
    Tao Y; Zhou Y; Tang L; Chen H; Feng Y; Shi Y
    Invest New Drugs; 2022 Aug; 40(4):831-840. PubMed ID: 35435628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse Drug Reactions of Acetaminophen and Ibuprofen in the Paediatric Population: Analysis of the Italian Spontaneous Reporting Database.
    Pelliccia V; Rossi S; Zollino I; Quagliarella F; Buonocore G
    Curr Pediatr Rev; 2022; 18(1):64-71. PubMed ID: 34503427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database.
    Crisafulli S; Cutroneo PM; Verhamme K; Ferrajolo C; Ficarra V; Sottosanti L; Di Giovanni V; Spina E; Trifirò G
    Eur Urol Focus; 2022 Sep; 8(5):1424-1432. PubMed ID: 34275763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.